Europe PMC

Background Although adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.Methods Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescrib

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Objective and design This prospective multicenter cohort study was conducted to identify and compare clinical factors associated with the effectiveness of commonly used biologics in Chinese patients with moderate-to-severe psoriasis.Subjects Patients from the SPEECH registry initiating treatment with ixekizumab, secukinumab, guselkumab, or ustekinumab were included.Treatment Guideline-recommended dosing; 3-month follow-up.Methods The primary endpoint was PASI90 response at 3 months. Multivariabl

Psoriasis and psoriatic arthritis (PsA) occasionally coexist with antinuclear antibody (ANA) positivity, cutaneous lupus erythematosus (CLE), or systemic lupus erythematosus (SLE), creating one of the most challenging therapeutic overlap scenarios in immunodermatology. Divergent immune pathways-IL-23/Th17-driven psoriatic inflammation versus type I interferon-mediated autoimmunity-generate unique vulnerabilities when systemic treatments are used. To synthesize treatment outcomes, lupus-related s

Psoriatic arthritis develops in up to one-third of individuals with psoriasis, typically following a prolonged subclinical phase. Diagnostic delays are common, often exceeding 2 years, and can result in irreversible joint damage. The growing recognition of this latent period has fuelled interest in earlier identification and interception. However, efforts are hampered by inconsistent definitions of early or subclinical psoriatic arthritis, insufficient prognostic tools, and an absence of consens

This study examined relationships between Early Maladaptive Schemas (EMS), emotion regulation, coping styles, and psoriasis outcomes in Istanbul, Turkey. Participants included 100 psoriasis patients (ages 25-45) and 107 healthy controls. Data were analyzed using structural equation modeling. Psoriasis patients scored significantly higher on six schemas: Emotional Deprivation, Approval Seeking, Pessimism, Self-Sacrifice, Punitiveness, and Unrelenting Standards (Cohen's d = 0.42-0.89). They also d

Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed. We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis. Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy. In the phase 1c trial, 32 patients consented to receive twice daily (BID) doses of placebo or DC-806 (200 mg or 800 mg) for 28 days. No ser

Background and objectives Psoriasis is a chronic inflammatory skin disease, and noninvasive diagnostic tools are essential for accurate diagnosis and treatment monitoring. Multiphoton microscopy (MPM) enables real-time, noninvasive skin imaging with submicron resolution. This study evaluated the diagnostic accuracy of MPM in psoriasis and its potential application in therapeutic monitoring.Patients and methods This prospective observational study enrolled 34 patients with psoriasis. It comprised

Objective This study aims to evaluate the clinical impacts of topical and/or oral administration of compounds rich in omega-3 fatty acids from various sources, such as oils and foods, on psoriatic lesions.Design A systematic review was carried out.Data sources Searches were conducted in six databases (PubMed, Cochrane, VHL, Scopus, Embase, and Web of Science) using descriptors related to fatty acids and psoriasis.Study selection Inclusion criteria were studies published in the last 10 years (201

Abstract Background Psoriasis patients in China face significant challenges due to insufficient disease knowledge and limited access to medical resources, creating a need for reliable educational tools. Objectives This multicenter consensus study aimed to systematically evaluate the consultation quality of mainstream Chinese large language models (LLMs) for psoriasis patient education. Methods "365 Questions on Psoriasis" was jointly compiled by 109 Chinese psoriasis experts. Using an expert

Background Despite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments.Methods We performed comprehensive RNA sequencing of skin and blood (n = 718) from prospectively-recruited, deeply-phenotyped discovery and re

Background Psoriasis is a chronic autoimmune skin condition that significantly impacts an individual's quality of life, resulting in physical discomfort, psychological distress, and compromised social well-being. However, there is limited understanding regarding the challenges faced by patients in Malaysia. This study examines the lived experiences of patients with psoriasis in Malaysia, focusing on the emotional, social, financial, and treatment-related challenges they face, as well as the copi

Background Psoriasis affects approximately 2% of the global population, with the IL-17A-STAT3 pathway mediating abnormal keratinocyte proliferation and inflammatory amplification. Solanum lyratum (Bai Ying) has long been used for skin disorders, and its steroidal alkaloids have anti-inflammatory potential, though the mechanisms remain unclear.Objective To elucidate the molecular basis and cytological efficacy of S. lyratum steroidal alkaloids in exerting anti-psoriatic effects via the IL-17A/STA

Introduction Treatment of moderate to severe psoriasis typically requires the use of multiple systemic therapies over a patient's lifetime. The efficacy and safety of systemic treatments are typically evaluated in clinical trials; however, patient registries are increasingly used to monitor long-term outcomes of systemic therapies for psoriasis in real-world settings. Psoriasis registries also generate important real-world evidence about psoriasis treatment that may facilitate a greater understa

Objectives To assess the incidence and risk factors for arrhythmias in patients with psoriatic arthritis (PsA).Methods We performed a cohort analysis of patients followed prospectively from 1994 to 2024. Participants were evaluated using standard protocols at 6-to-12-month intervals. The following events were assessed: (1) atrial tachyarrhythmia (including atrial fibrillation and supraventricular tachycardia); (2) ventricular tachyarrhythmia and (3) bradycardia/pacemaker. The cumulative incidenc

Abstract Atopic dermatitis and psoriasis are two dermatological diseases that affect the mental health of patients. The purpose of this research is to investigate the comparison of the psychometric characteristics of two groups of patients with psoriasis and atopic dermatitis respectively focusing on depression, personality, hostility and psychosomatic burden. Τhe sample was consisted by 100 patients with psoriasis and 40 patients with atopic dermatitis, respectively. Specific questionnaires we

No abstract supplied.Weiterlesen

Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient's reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination l

Introduction Psoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surfa

Introduction The German national psoriasis registry PsoBest collects long-term data on the effectiveness, safety, and tolerability of systemic treatments for psoriatic disease. Here, we describe patient characteristics and the safety and effectiveness of apremilast for the treatment of psoriatic disease in Germany based on data from PsoBest.Methods This was a descriptive analysis of observational data collected from PsoBest using cross-sectional (baseline characteristics) and longitudinal (outco

Background Psoriasis is a systemic inflammatory disease associated with cardiopulmonary comorbidities. Nail psoriasis, quantified by the Nail Psoriasis Severity Index (NAPSI), is a marker of severe disease. While pulmonary arterial hypertension (PAH) is reported more frequently in psoriasis, the specific correlation between nail psoriasis severity and PAH remains underexplored.Objective To investigate the correlation between NAPSI scores and the presence or severity of PAH in patients with psori

Introduction Nail psoriasis is a common, treatment-refractory manifestation of psoriasis. Smoking is a key environmental factor implicated in nail and articular psoriasis. While smoking's association with cutaneous psoriasis is well-studied, its relationship with nail psoriasis remains less explored.Objective The primary objective of this study was to investigate the impact of smoking on the severity of nail psoriasis and arthritic psoriasis in patients with nail psoriasis.Methods Data from 1044

Aim The current work highlighted the preparation method of Tanshinone IIA, Glycyrrhetinic acid Emulsion with eutectic (GT-eEmu) and investigated its effectiveness in the internal and external treatment of psoriasis.Materials & methods The optimal prescription ratios of the emulsions were screened based on single-factor and orthogonal experiments, in which the appearance, particle size, centrifugal stability, and placement stability of the emulsion were used as indicators. On this basis, the

Purpose Psoriasis is frequently associated with dyslipidemia, yet the role of specific unsaturated fatty acid (UFA) metabolic pathways in disease pathogenesis and treatment response remains poorly understood. This study aimed to characterize the landscape of UFA metabolic reprogramming in psoriasis and evaluate its clinical relevance for predicting response to biologic therapy.Patients and methods We performed an integrated multi-omics analysis incorporating transcriptomic data from human psoria